Missense mutations in the p53 coding gene cause loss and gain of function. We have identified a hotspot mutation, p53
Missense mutations in the p53 coding gene cause loss and gain of function. We have identified a hotspot mutation, p53 N236S , which results in the aggressive progression of tumorigenesis in a knock-in mouse model. To understand the biological significance of the p53 N236S mutation, we performed ChIP-onchip combined with microarray assay to profile the regulated gene expression pattern. We could classify the p53 N236S mutant function into six categories. Among these, we reveal a new aspect of gain of function, the enhancement of wild-type p53 function, which has not been reported previously. We also show the existence of residual wild-type p53 function in p53 N236S . Our data shed light on understanding the difference between this type of low-incidence hotspot p53 mutations and classical hotspot mutations.
Keywords: expression profile; gain of function; p53 N236S ; transcription profile TP53 (Trp53 in mouse) is a critical tumor suppressor gene encoding p53 protein and an essential transcription factor that regulates cell cycle arrest, apoptosis, and senescence [1, 2] . More than 50% of human cancer types harbor missense mutations in TP53, and some mutant p53 proteins have lost the function of wild-type p53 protein (loss of function, LOF) and gained the oncogenic function (gain of function, GOF) in promoting migration, invasion, and metastasis of cancer cells. Mutant p53 also can confer anti-apoptotic ability on tumor cells, thus promoting carcinogenesis and drug resistance, and causing poor patient prognosis [3] [4] [5] . In p53 mouse models, p53 missense mutations produce more aggressive and metastatic tumors compared to p53 null or heterozygous mice [6] [7] [8] , suggesting that GOF is the key characteristic of mutant p53. However, the underlying mechanism of GOF is still unclear. Of the three GOF mechanism models with mutant p53, direct and indirect transcription regulations are involved, which enable cells to gain oncogenic functions and proliferation advantages [2, 9] . Thus, the transcription profile combined with expression profile will help us predict and understand the GOF of each particular p53 mutant.
By means of multiomics, proteome, DNA interactome (ChIP-seq), and transcriptome (RNA-seq/microarray) analyses, the proteasome machinery has been identified as a common target of p53 missense mutants, which affects protein homeostasis and inhibits multiple tumorsuppressive pathways [10] . In a mouse model with p53 R172H mutation, spontaneous osteosarcomas occurred with increased metastasis compared with p53 null mice. The RNA sequencing analysis of those tumors identified a cluster of small nucleolar RNAs that are highly upregulated in p53 mutant tumors due to transcription regulation by Ets2 [11] . A transcriptome profiling of floxuridine (FUdR)-treated SW480 cells has shown that differentially regulated genes upon drug treatment in SW480 cells were mostly targeted by the transcription factors (such as NFY, E2F1) known to interact with mutant p53 [12] . These data demonstrate the power of omics in understanding the GOF of p53 mutants.
We previously found p53 N236S (p53 N239S in human, p53S) in three independent tumorigenic mouse cell lines derived from telomere dysfunction. While p53S had lost its ability to regulate cell cycle arrest and apoptosis, it also gained unique functions in cross-talking with oncogenes and regulating double minute chromosomes formation [13, 14] . The p53S is a unique missense mutation. Although the mutation rate in human cancer is only 0.16% across tumors of all cancers, the mutation is involved in wide tumor spectrum including cancers originated from the hematopoietic system, bladder, liver, soft tissue, esophagus, breast, brain, lung, and stomach [15] . Furthermore, a recent study developed a statistical algorithm to identify recurrently mutated residues in tumor samples and uncover detected low-incidence hotspots in highly mutated genes and predicted that these hotspots might be under selection and might confer important clinical phenotypes in cancer patients [16] . Knowing this, it is surprising that we find the mouse model of p53 N236S displayed a very similar phenotype as the mouse model of hotspot mutation p53 R172H [7, 14] . p53S is one of these less common but recurrent mutations in human cancers and has been labeled as a hotspot mutation in the TCGA database according to this new algorithm. It would be interesting to profile the expression regulated by this kind of hotspot mutation.
Here, we used Chromatin immunoprecipitation (ChIP)-on-chip combined with microarray assay to profile the regulated gene pattern change in p53S compared with wild-type p53, and null function of p53 (p53 null) in mouse embryonic fibroblasts (MEFs). Our data revealed a new aspect of the gain of function and the residual wild-type function of p53S, which might shed light on understanding the biological significance of these types of low-incidence hotspot mutations.
Materials and methods

Bioinformatic analysis
The analysis process is shown in Fig. 1 . The detailed protocol is as following: the Bioinformatics ExperT SYstem (BETSY) was applied to automate the development of workflows [17] . The single sample gene set enrichment analysis (ssGSEA) [18] was applied for analyzing the ChIP-onchip data and microarray data. The enrichment peaks in the individual gene promoter were used as DNA binding affinity for ChIP-on-chip ssGSEA analysis. The expression signals of the microarray were used for ssGSEA analysis. Hallmark gene set from Molecular Signatures database [19] was used for ssGSEA analysis. The heatmaps were plotted with hierarchical clustering, with or without centering (mean) and normalization (variance). The PANTHER [20, 21] (protein annotation through evolutionary relationship) classification system was used for overview Gene Ontology analysis. CIRCOS software [22] was used for generating circos plot. Cytoscape, ClueGO, and CluePedia [23] [24] [25] were used for gene ontology enrichment analysis, the parameters are the following: network specificity is medium, significant P value (Fisher's Exact Test with a Bonferroni correction for multiple hypothesis) is 0.01. Level 7 is the max GO tree interval, and the kappa score is 0.5.
The calculation of the percentage change of ssGSEA scores from ChIP-on-chip data of p53S comparing with WT: Due to the ssGSEA scores could be negative value in either wild type p53 (WT) or p53S (p53SS) or both, we could not calculate the fold change by directly dividing the p53SS score by the WT score. We calculated the percentage of change as the following: first, we subtracted the scores from p53SS from WT, the negative value indicates a decrease in pathway score, the positive value indicates an increase. Then, the obtained delta value is divided by the absolute value of WT score, the resulting value indicates decreased or increased change. This value became the percentage of change.
To investigate the correlation between p53S DNA occupancy and expression regulation, we first plotted a Venn diagram to visualize the differential regulation pattern between wild-type p53 and p53S. The gene promoters occupied by wild-type p53 or p53S were calculated according to the enrichment peaks of ChIP-chip data. The number of gene promoters occupied by wild-type p53 calculated by the genes whose ChIP-chip peaks only enriched in wildtype p53. The number of gene promoters occupied by p53S calculated by the genes whose ChIP-chip peaks only enriched in p53S. The number of gene promoters occupied by wild-type p53 and p53S calculated by the genes whose ChIP-chip peaks enriched in both wild-type p53 and p53S. Then, the eBayes method was used to determine differential expression [26] regulation between wild-type p53 and p53S. To clarify the gain or loss function of p53S, we first compared genes regulated by wild-type p53 or p53S with p53 À/ À in microarray data. Then, we calculated the number of genes whose expressions were, based on the gene expression level in p53 À/À , up-regulated, down-regulated, and had no change; a P value of ≤0.05 was considered significant, false discovery rate is ≤0.05. Genes that did not match the gene list between microarray data and ChIP-chip data were shown as no match.
Mice and the MEF cell lines
The p53 S/S knock-in mice were established and characterized previously [14] . 
Chromatin immunoprecipitation-on-chip
The cell lysates from the wild-type (WT) and p53 S/S MEFs were collected, and cross-linked by 1% formaldehyde, followed by sonication using a Diagenode Bioruptor UCD-200 at high power in ice water. Sonicated fragments ranged in size from 200 to 1000 bp. After sonication, samples were centrifuged at 13 000 g for 10 min. The supernatant was preabsorbed with ChIP-grade protein G magnetic beads (CST) and then incubated with the same beads together with anti-p53 antibodies (CST) overnight at 4°C. The beads were then washed and eluted by elution buffer (1% SDS, 0.1 M NaHCO3). Twenty microliters of 5 M NaCl was then added to the eluted product and incubated at 65°C overnight to reverse the crosslinking. Immunoprecipitated genomic DNA was then purified using a QIA-GEN Purification Kit and dissolved in ethidium bromide buffer for the following qPCR QC assay and ChIP-onchip analysis. Fig. 1 . The analysis process of GOF profiles of p53S. Gene ontology analysis was performed by PANTHER system, functionally grouped network was constructed by ClueGO, and the eBayes method was used for Venn diagram drawn and calculated.
The whole-genome amplification (WGA) and array hybridization were performed by a commercial service (KangChen Bio-tech com., Shanghai, China). In brief, the immunoaffinity-enriched DNA was amplified using a WGA kit from Sigma-Aldrich [GenomePlex Ò Complete Whole Genome Amplification (WGA2) kit]. For array hybridization, Roche NimbleGen's Mouse ChIP-on-chip 2.1M Deluxe Promoter Array was used. The log2-ratio obtained from raw data was normalized by R packages (Ringo, limma, and MEDME), and significant positive enrichment peaks were found by NimbleScan v2.5, for our data, peaks with false discovery rate (FDR) ≤0.05 are mapped to transcripts.
Microarray
Mouse embryonic fibroblast cell samples were harvested from e13.5 p53 +/+ or p53 S/S mouse embryos. To reduce individual heterogeneity, three MEF cell samples were collected from embryos of three individual pregnant mice. Skeletal muscle or tumor tissue samples were harvested from wild-type C57BL/6 mice or p53 S/S mice. To reduce individual heterogeneity, three tissue samples collected from three individual mice were pooled to create one test sample. For microarray assay, total RNA was extracted from samples using the Trizol reagent (Invitrogen, Carlsbad, CA, USA) and was purified with the mirVana miRNA Isolation Kit (Ambion, Austin, TX, USA), according to manufacturer's protocol. The RNA samples analyzed by Agilent mouse mRNA Array chips (8 9 60K format, Agilent, Carpinteria, CA, USA). The array data were analyzed for data summarization, normalization, and quality control using the GENESPRING software V12 (Agilent).
Western blotting and antibodies
The cells were lysed in RIPA buffer containing Protease Inhibitor Cocktail kit (Roche, Basel, Switzerland). About 50 lg of total proteins was separated by SDS/PAGE and then transferred to poly(vinylidene difluoride) membrane. After blocking in 2% BSA for 1 h at room temperature, membranes were incubated with primary antibodies overnight at 4°C or 2 h at room temperature. The membranes were then incubated with horseradish peroxidase-labeled secondary antibodies and visualized with ECL. The primary antibodies used are the following: antip53Ab1(Pab421) (1 : 500, Calbiochem, Billerica, MA, USA), anti-p19 ARF (clone 5-C3-1) (1 : 1000, Millipore, Burlington, MA, USA), anti-Caspase 3 (1 : 1000, CST, Danvers, MA, USA), anti-cMyc (1 : 1000, CST), and anti-ß-actin (1 : 8000, Millipore).
Cell cycle analysis
Cell cycle analysis was done by flow cytometry (BD, FACS Vantage SE). Data were analyzed by Flowjo. Percentages of cells in G1, S, and G2 were determined using the DeanJett-Fox algorithm.
Results
Transcription profile of p53S
To get the overall idea of the differential transcription regulation from wild-type p53 or p53S, we first plotted a Venn diagram to visualize the differential regulation pattern between wild-type p53 and p53S. We found that only 18.8% (950/5044) genes are commonly regulated, suggested that p53S transcription pattern is very different with wild-type p53 ( Fig. 2A) . We then imported the ChIP-on-chip data into the PANTHER system for GO term enrichment analysis. Genes with significant GO term enrichment (P < 0.05, percentage of gene number >10%) were extracted to draw a chromosome distribution map, p53S showed more enrichment peaks at chromosomes 2, 7, 9, and 19 than wildtype p53, suggesting that more p53S occupancy occurred in those chromosomes (Fig. 2B) . Genes regulated only by p53S were used for the functionally grouped network constructed by ClueGO. The data showed that compared with wild-type, p53S showed significant enrichment in terms of system development, synapse assembly, ossification, organ morphogenesis, skeletal development, muscle structure development, etc., which are essential regulation pathways for embryonic development. The p53S also showed significant enrichment in cell migration, cell localization, leukocyte proliferation, mesenchyme development and differentiation, etc., which are essential regulation pathways for cellular process (Fig. 3) . These data fit the phenotypes manifested in the p53S mouse model well [14] . To further understand the transcription pattern of p53S, we performed ssGSEA analysis for ChIP-on-chip data. The enrichment peaks in the individual gene promoter were used as the parameter for DNA binding affinity, the Hallmark gene set was used as the reference [19] , and the ssGSEA scores were used to plot the heatmaps. First, we plotted the heatmap with all the pathways irrespective of the value of their scores. The heatmap showed that some pathways were highly scored in both wild-type (WT) and p53S (p53SS) MEFs, such as ALLOGRAFT_REJECTION, COAGULATION, COMPLEMENT, XENOBIOTIC_METABOLISM, FATTY_ACID_METABOLISM, CHOLESTEROL_ HOMEOSTASIS, etc. These data suggested that these pathways were highly regulated by both wild-type p53 and p53S (Fig. 4A) . On the other hand, some pathways were scored negatively high in both WT and p53SS MEFs, such as MYC_TARGETS_V2, REACTIVE_ OXIGEN_SPECIES_PATHWAY, NOTCH_SIGNAL-ING etc. These data suggested that these pathways were not regulated by both wild-type p53 and p53S. Other pathways in the Hallmark gene set were more or less differentially regulated (Fig. 4A) . If we draw the heatmap by clustering the scores with centering and normalization, we could separate the pathways into two groups: those which are more regulated by wild-type p53 and those which are more regulated by p53S (Fig. 4B) . We assumed that those pathways regulated by p53S endowed the gain of function of p53S, including pathways involved in DNA damage response, estrogen response, and immune response, etc., by regulating their genes' promoters (Fig. 4, Table 1 ).
Since we observed that several pathways involved in DNA damage response were regulated by p53S, we then try to compare the transcription profile of p53S before and after DNA damages induced by doxorubicin. Interestingly, almost all Hallmark pathways showed a dramatic change after doxorubicin treatment except MYC_TAR-GETS_V1 (Fig. 4C) . The clustered heatmap showed that the pathways were less regulated by p53S after doxorubicin treatment included APOPTOSIS, G2M_CHECK-POINT, MITOTIC_SPINDLE, UV_RESPONSE_DN, KRAS_SIGNALING_DN etc., and the pathways regulated more by p53S after doxorubicin treatment included P53_PATHWAY, HYPOXIA, UV_RESPONSE_UP, KRAS_SIGNALING_UP, REACTIVE_OXIGEN_SPE-CIES_PATHWAY, etc. (Fig. 4D) .
Together these ChIP-on-chip data suggested the differential regulation of p53S with wild-type p53, as well as in the condition of DNA damage. However, without expression data, it is hard to predict the functional change in p53S. Thus, we further investigated the expression profile of p53S by microarray assay.
Expression profile of p53S revealed six categories of functional changes
To investigate the functional change in p53S, including the loss of function and the gain of function, we compared the expression profile of p53S with wild-type p53 and p53 null mutant (complete loss of p53 function due to knock out of p53 gene) by microarray assay. In the same microarray assay, we also compared the expression profile of p53S with wild-type p53 and p53 null mutant after doxorubicin treatment. We then group the microarray data and analyzed ssGSEA through BETSY system. The Hallmark gene set was used for enrichment analysis.
In the first group, we compared the samples without doxorubicin treatment. The samples were clustered by the ssGSEA scores of Hallmark gene set. The heatmap was clustered into six major clusters according to the expression pattern. Comparing the expression pattern of p53S with p53 null or wild-type p53, we could identify six categories of the functional changes occurred in p53S MEFs. The category 1 was the cluster with decreased pathway regulation in p53 null and p53S comparing to wild-type MEFs, which suggested that the p53S had lost the function of regulating the expression of genes in these pathways, like the p53 null. We identified it as the loss of wild-type function for p53S (Fig. 5A, No.1 ). The category 2 was the cluster with decreased pathway regulation only in p53S, but not in p53 null or wild-type MEFs, which suggested that the p53S had gained the new function of suppressing the Fig. 3 . The functionally grouped network of genes regulated by p53S comparing with wild-type p53 by ClueGO. The selected terms in a functionally grouped annotation network reflect the relationships between the terms based on the similarity of their associated genes. The groups are randomly colored. The size of the nodes reflects the statistical significance of the terms, and the functional group is annotated by the most significant term. The edges between nodes represent association strength between the terms. Comparing with wild-type, p53S showed significant enrichment in terms in essential regulation pathways for embryonic development, as well as in pathways for cellular process.
expression of genes in these pathways. We identified it as the gain of suppressing function for p53S (Fig. 5A , No. 2). Category 3 was the cluster with increased pathway regulation only in p53S, but not in p53 null or wild-type MEFs, which suggested that the p53S had gained the new function of activating the expression of genes in these pathways. We identified it as the gain of activating function for p53S (Fig. 5A, No. 3 ). Category 4 was the cluster in which the regulation of pathways increased from p53 null to wild-type to p53S, which meant that the p53S obtained the strongest expression regulation of genes involved in these pathways. We identified it as the gain of additional wildtype activating function for p53S, meaning that p53S had gained additional activating function for those pathways (Fig. 5A, No. 4) . Categories 5 and 6 were the clusters showing the remaining regulating function for p53S compared to wild-type, but not in p53 null MEFs. The category 5 cluster showed increased pathway regulation in p53S and wild-type compared to p53 null MEFs (Fig. 5A, No. 5 ). The category 6 cluster showed decreased pathway regulation in p53S and wild-type compared to p53 null MEFs (Fig. 5A , No. 6). We identified these two categories as the remnants of wild-type-activating function or of wild-type-suppressing function. The pathways without consistent scores across the samples are excluded, such as MTORC1_SIGNALING, PANCREAS_BETA_-CELLS (Fig. 5A) .
In the second group, we compared the expression profile of p53S with wild-type p53 and p53 null mutant after doxorubicin treatment. We could still identify those six categories as in the first group, but some of the pathways fell into a different category compared with the first group (Fig. 5B) .
Knowing that doxorubicin treatment will induce p53 related pathways involved in DNA damage response, thus, the gain of function or loss of function in p53S MEFs would become more obvious when MEFs were treatment by DNA damage stimulation. We then compared the expression profiles of wild-type and p53S MEFs before and after doxorubicin treatment. By clustering the ssGSEA scores of Hallmark gene set, the samples was nicely grouped according to their genotypes (WT or p53SS), and with or without doxorubicin treatment, which suggested that our analysis is generally in the right track (Fig. 6 ). The first cluster of pathways displayed enhanced pathway regulation in either p53SS MEFs (p53SS) or p53SS MEFs treated with doxorubicin (Dox_p53SS) comparing with wild-type MEFs (p53WT) or wild-type MEFs treated with doxorubicin (Dox_p53WT) (Fig. 6 , Gain of function). Among these pathways, we could identify DNA_REPAIR, ALLOGRAFT_REJECTION, IL2_ STAT5_SIGNALING, IL6_JAK_STAT3_SIGNALING, COMPLEMENT, COAGULATION, etc., which were also found as the category 4 in the Fig. 5A . These pathways were activated gradually from p53WT, Dox_p53WT, p53SS, to Dox_p53SS. This pattern fitted very well with the category 4: gain of wild-typeactivating function. On the other hand, some pathways were activated only in p53WT, and became further activated in Dox_p53WT, but not in p53SS or Dox_p53SS (Fig. 6 , Loss of function). This pattern fitted very well with the category 1: loss of function. Among these pathways, we could find pathways like P53_PATHWAY, ANGIOGENESIS, ESTROGEN_ RESPONSE_LATE, ANDROGEN_RESPONSE, which were identified as category 1 in the first group (Fig. 5A , No.1). Besides, we could also identify the pathway clusters that remained similar regulation pattern as in wildtype MEFs, these pathways could be either p53S remaining function or independent of p53S function (Fig. 6, Remaining Function) .
To validate the function of p53S revealed by ssGSEA assay, we performed functional assays with (Fig. 7A) , which confirmed the up-regulation of cMyc, E2F, and allograft rejection pathways in Fig. 5 . After 24 h of doxorubicin treatment, we could observe obvious cleavage of Caspase-3 in WT MEFs, indicating the occurrence of apoptosis. We could also observe the cleavage of Caspase-3 in p53 S/S , MEFs, but not in p53 À/À MEFs (Fig. 7B) (Fig. 7C,D) . Together these data indicated that p53S could maintain partial function in inducing apoptosis upon doxorubicin-induced DNA damages. These data are consistent with our previous data from the mouse tissue, in which p53S mouse tissue showed residual Bax and PUMA activation upon irradiation [14] . Together the expression profile of p53S revealed six categories of functional changes for p53S, which might work through p53S occupancy of those gene promoters and activating or suppressing the related pathways. Thus, we tried to combine the ChIP-onchip data together with microarray data to investigate the correlation between p53S DNA occupancy and expression regulation. Since p53 null MEFs have no wild-type or mutant p53 protein, all genes in p53 null MEFs were regulated independently of p53. Thus, by comparing the gene expression level with p53 null, we could distinguish the gene expression changes that are regulated by wild-type p53 or p53S (Fig. 8) . After deducting unknown transcripts, the data indicated that 799 of 1967 genes (40.6%) were occupied by wild-type p53 and up-regulated in expression level, while 893 of 1951 genes (45.8%) were occupied by p53S and up-regulated (Fig. 8, UP) . It also showed that 774 of 1967 genes (39.3%) were occupied by wild-type p53 and down-regulated in expression level, while 676 of 1951 genes (34.6%) were occupied by p53S and down-regulated (Fig. 8, DOWN) . There was also a small percentage of genes which were either occupied by wild-type p53 or p53S but did not change in expression level (Fig. 8, NO CHANGE) or did not match the gene list in microarray data (Fig. 8, NO MATCH) . These data suggested that p53S could occupy DNA promoters of a variety of genes and regulated their expression, just like wildtype p53.
We further try to match the DNA occupancy pattern of p53S with the loss or gain of function pattern by comparing the regulation of pathways in Hallmark gene set. To compare the change in p53S DNA occupancy with wild-type p53, we calculated the ssGSEA scores of target genes and the percentage of change. Then we compare the pathways with DNA occupancy change in p53S with the pathways in the six categories of p53S functional changes. For a clear view, we also included the original ssGSEA scores for wild-type p53 or p53S DNA occupancy (Table 1) . Interestingly, we did observe more dramatic changes in p53S DNA occupancy in the categories of gain of unique activating function and gain of activating wild-type p53 activity. For those pathways with DNA occupancy changes less than 50%, the ssGSEA scores for both wild-type and p53S are high, such as COAGU-LATION, COMPLEMENT, and ALLOGRAFT_RE-JECTION (Table 1, category 3 and 4) . The trend of changes was not obvious with other categories of functional change. These data implied that p53S achieved its gain of function by DNA occupancy.
By calculating the percentage of fold change in ssGSEA score for DNA occupancy, we also observed three pathways with extreme high fold change: TGF_BETA_SIGNALING (>1000%), MYC_TAR-GETS_V1 (>2000%), and PANCREAS_BETA_-CELLS (>1000%). All three pathways had extreme low absolute value for ssGSEA scores of wild-type p53, which might indicate unreliable data (Table 1) .
Discussion
Functional changes in p53 mutant protein include lossof-function and gain of function, which facilitate the tumorigenesis driven by mutant p53 [2, 3] . It is believed that the mutant p53 caused ineffective binding of p53 to consensus DNA sequences in target gene promoters attenuating tumor-suppressive mechanisms and reducing barriers to cell proliferation; thus, mutant p53 gain novel function primarily through protein-protein interactions with other transcription factors [27] . To understand GOFs of p53S, we combined ChIPon-chip and microarray data to draw a transcription and expression map of p53S. By ssGSEA analysis, we could cluster and identify six categories for the functional change in p53S comparing with p53 wild-type or p53 null function. Among these six categories, we were surprised to find a category that is conferred by wild-type p53, while p53S mutant gained a change in DNA occupancy and resulted in expression activation of pathways involved in this category (Fig. 5 and Table 1 , category 4). These data imply that p53S did not just maintain partial wild-type p53 function, but gained stronger function. We did observe a further strengthening of this gain of function upon the DNA damage stimulation induced by doxorubicin, which further confirmed the existence of this type of gain of function (Fig. 6) . We are still not clear how this type of function contributes to the high incidence of the tumorigenesis in the p53S mouse model, further experiments are needed to dissect this type of function.
Although it is still not clear whether mutant p53 could directly bind to the promoters of a new set of consensus DNA sequences and result in a gain of new functions, increasing evidences suggested that different p53 mutant bound to different set of gene promoters [28] [29] [30] , which might contributed to the determination of tumor spectrum and GOF activity. We also observed a group of pathways that were highly expressed in p53SS MEF cells only (Fig. 5, category 3) , and with high p53S DNA occupancy (Fig. 4 and Table 1 ). This group of pathways included HEME_METABOLISM, INTERFERON_ALPHA_RESPONSE, INTERFER-ON_GAMMA_ RESPONSE, and SPERMATOGEN-ESIS. These pathways might contribute to the abnormally high inflammatory response occurring in p53S mouse models, studies are being carried out to explore this part of gain of function of p53S.
Another interesting data is that around 80% of genes occupied by wild-type p53 were up-regulated (40.6%) or down-regulated (39.3%) in the expression level. Similar to this, around 80% of genes occupied by p53S were up-regulated (45.8%) or down-regulated (34.6%). These data are similar to the 60% DNA occupancy of mutant p53 in MDA-MB-231 [10] . This high DNA occupancy for mutant p53 implied that it possesses additional new sites of transcription regulation. We noticed that the HALLMARK_KRAS_SIGNA-LING_UP pathway is obviously up-regulated in p53S MEFs with or without Dox treatment, while the HALLMARK_KRAS_SIGNALING_DN pathway is down-regulated (Fig. 5A,B) , suggesting the p53S positively regulated Ras signaling pathway. This result is consistent with our previous finding that p53S co-operated with Ras in tumorigenesis [13] . The p19 ARF -coding gene, Cdkn2a, is in the HALLMARK_ E2F_TARGETS and HALLMARK_ALLOGRAF-T_REJECTION pathways. Very interestingly, our data analysis showed that both pathways were highly up-regulated in p53S MEFs with or without Dox treatment (Fig. 5A,B) . We also confirmed that the p19 ARF protein level was up-regulated in p53SS MEFs before and after doxorubicin treatment (Fig. 7A) . Together these data indicated that p53S up-regulated p19 ARF , which might contribute to the functional regulation of E2F and allograft rejection pathways. These data are consistent with our previous data from mouse tissue showing that p53S could up-regulate p19 ARF signaling pathways, and the p19 ARF could in turn stabilize p53S and enhance its gain of function [13, 14] .
Comparing the functional alteration of p53S with the classical hotspot p53 mutations (Table 2) , we could see the residual apoptosis function, the regulation of p19 ARF signaling pathways, and the regulation of double minute chromosomes are unique features among p53 mutations, which could contribute to the gain of functions of p53S. To clarify the clinical significance of these new functions in tumorigenesis or cellular senescence, further functional studies need to be conducted.
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